Investment
Features
FeesSafety
Academy
More
Pluang+

Compare MACOM Technology (MTSI) vs ResMed Inc. (RMD) Price & Performance

MACOM TechnologyTrade
ResMed Inc.Trade

Price performance (Past 24H)

Key statistics

MACOM Technology vs ResMed Inc. — how do they compare? MACOM Technology trades at $283.02 (market cap $20.99B), while ResMed Inc. trades at $219.5 (market cap $31.89B). The key difference: ResMed Inc. is the larger of the two by market cap, and ResMed Inc. pays a 1.19% dividend while MACOM Technology pays none. Which is the better fit depends on your goals.

MTSIRMD
Market Cap
$20.99B$31.89B
Sector
TechnologyHealth
52-Week High
$409.68$283.28
52-Week Low
$122.18$182.82
Enterprise Value
$20.70B$31.24B
Dividend Yield
1.19%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

MACOM Technology

No Aura AI signal available yet.

ResMed Inc.

ResMed (RMD) trades at $221.05, down 3.2% amid a bearish technical signal, though it holds above key support at $218. The company reported strong Q4 2026 results with EPS of $2.95 beating estimates, and revenue grew 9% to a record $1.5 billion. However, weaker fiscal 2027 revenue guidance has pressured the stock. Fundamentals remain solid with a 26.94% net income margin and robust cash flow from operations of $1.75 billion in 2025.

The outlook is mixed; strong profitability and consistent earnings beats support upside toward the $235.70 consensus price target, but near-term sentiment is cautious due to the soft sales forecast and ongoing legal investigations. Key risks include competitive pressures and execution on guidance. Institutional buying by firms like HSBC and Canada Pension Plan provides confidence in long-term value.

Returns comparison

Trailing returns across standard periods

About MACOM Technology

MACOM develops analog, radio frequency, microwave, and optical semiconductors. Its components are used in telecommunications, data centers, industrial systems, aerospace, and defense applications.

Read more on MTSI

About ResMed Inc.

ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.

Read more on RMD